TYN-21

TYN-21 is an investigational **paclitaxel** formulation being developed by **BW Therapeutics**. It uses a novel polymer excipient to markedly increase paclitaxel solubility without the need for Cremophor EL or albumin-based delivery, positioning it as a reformulated taxane chemotherapy product intended to retain paclitaxel's established antineoplastic activity while potentially improving formulation and tolerability characteristics. As a paclitaxel-based agent, its therapeutic effect is expected to arise from microtubule stabilization, which disrupts mitotic spindle dynamics and inhibits cancer cell division. The specific cancer indications and clinical development stage were not explicitly provided in the supplied context.